Product Information : Achondroplasia Treatment
We provide information
about BioMarin’s products for healthcare professionals.
Product Information
Achondroplasia drug
VOXZOGO® for subcutaneous injection
0.4mg/0.56mg/1.2mg
VOXZOGO® has a mechanism of action consistent with the pathophysiology of Achondroplasia.
It is a drug that promotes sustained bone growth.
| Generic Name | Vosolitide (genetical recombination) preparation |
|---|---|
| Indication | Achondroplasia epiphyseal closure |
| Dosage and Administration | The usual dose of vosolitide (genetical recombination) is 15 mg/kg for patients 2 years of age or older, and 30 mg/kg for patients under 2 years of age by subcutaneous injection once daily. However, the single dose should not exceed 1 mg. |
Materials on Our Products
For more information on diseases and products, please refer to the following PDF documents.
(*Based on the electronic package insert revised in December 2023, we are currently revising the following materials other than the Package Insert. Please wait for a while until they are updated to the revised version.)
Medical Reference
BioMarin Pharmaceutical Japan K.K. has established a medical information site " Medical Plus " For healthcare professionals .
Patient Support Program
Voxzogo Friends is a website for people with Achondroplasia and their families who are receiving VOXZOGO® .
